WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H540301
CAS#: 25717-80-0
Description: Molsidomine is a NO donor and annexin A2 inhibitor. It inhibits PDGF-induced smooth muscle cell migration, suppresses carotid artery neointima formation, and prevents activated platelet adhesion.
Hodoodo Cat#: H540301
Name: Molsidomine
CAS#: 25717-80-0
Chemical Formula: C9H14N4O4
Exact Mass: 242.10
Molecular Weight: 242.235
Elemental Analysis: C, 44.63; H, 5.83; N, 23.13; O, 26.42
Synonym: Corvaton; Morsydomine; N-(Ethoxycarbonyl)-3-(4-morpholinyl)sydnone imine; SIN-10; SIN10; SIN 10; Molsidomine
IUPAC/Chemical Name: (ethoxycarbonyl)(3-morpholino-1,2,3-oxadiazol-3-ium-5-yl)amide
InChi Key: XLFWDASMENKTKL-UHFFFAOYSA-N
InChi Code: InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3
SMILES Code: O=C([N-]C1=C[N+](N2CCOCC2)=NO1)OCC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 242.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Zordan P, Sciorati C, Campana L, Cottone L, Clementi E, Querini PR, Brunelli S. The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. Eur J Pharmacol. 2013 Sep 5;715(1-3):296-303. doi: 10.1016/j.ejphar.2013.05.007. Epub 2013 May 23. PubMed PMID: 23707352.
2: Parfenyuk EV, Dolinina ES. Design of silica carrier for controlled release of molsidomine: effect of preparation methods of silica matrixes and their composites with molsidomine on the drug release kinetics in vitro. Eur J Pharm Biopharm. 2014 Nov;88(3):1038-45. doi: 10.1016/j.ejpb.2014.09.007. Epub 2014 Sep 28. PubMed PMID: 25269886.
3: Tirone M, Conti V, Manenti F, Nicolosi PA, D'Orlando C, Azzoni E, Brunelli S. Nitric Oxide Donor Molsidomine Positively Modulates Myogenic Differentiation of Embryonic Endothelial Progenitors. PLoS One. 2016 Oct 19;11(10):e0164893. doi: 10.1371/journal.pone.0164893. eCollection 2016. PubMed PMID: 27760216; PubMed Central PMCID: PMC5070765.
4: Idrisova EM, Kladieva EA, Borovkova NV, Vorob'eva EV, Chernov VI, Karpov RS. [Long-acting isosorbide dinitrate and molsidomin in the treatment of effort angina in patients with arterial hypotension]. Ter Arkh. 2002;74(6):63-6. Russian. PubMed PMID: 12136489.
5: Żorniak M, Mitręga KA, Porc M, Krzemiński TF. New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology. Can J Physiol Pharmacol. 2017 Feb;95(2):111-121. doi: 10.1139/cjpp-2016-0251. Epub 2016 Oct 4. PubMed PMID: 27918857.
6: Wildgrube HJ, Ostrowski J, Chamberlain J, Gärtner W, Stockhausen H. Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers. Arzneimittelforschung. 1986 Jul;36(7):1129-33. PubMed PMID: 3768083.
7: Messin R, Karpov Y, Baikova N, Bruhwyler J, Monseu MJ, Guns C, Géczy J. Short- and long-term effects of molsidomine retard and molsidomine nonretard on exercise capacity and clinical status in patients with stable angina: a multicenter randomized double-blind crossover placebo-controlled trial. J Cardiovasc Pharmacol. 1998 Feb;31(2):271-6. PubMed PMID: 9475269.
8: The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group. Lancet. 1994 Jul 9;344(8915):91-7. PubMed PMID: 7912393.
9: Fach WA, Kostanecka T, Kober G. [Long-term antihypertensive effect of delayed-action molsidomine]. Z Kardiol. 1994 Sep;83(9):646-51. German. PubMed PMID: 7801667.
10: Weidemann H, Schober B, Schuon J. Comparative study of long-term effects of Molsidomin 8 mg (slow release form) and ISDN 40 mg (slow release form) on angina pectoris and ischaemic ST-segment depression during maximal bicycle-ergometry in patients with coronary insufficiency. Eur Heart J. 1987 Oct;8 Suppl G:63-9. PubMed PMID: 3443128.
11: Monnin JL, Vinel JP, Le Quellec A, Pascal JP, Taourel P, Bruel JM, Blanc F, Michel H, Ciurana AJ. [Evaluation of the effects of molsidomine and propranolol-molsidomine combination on portal hemodynamics by pulsed Doppler ultrasound]. Gastroenterol Clin Biol. 1992;16(10):745-50. French. PubMed PMID: 1478400.
12: Kang M, Hashimoto A, Gade A, Akbarali HI. Interaction between hydrogen sulfide-induced sulfhydration and tyrosine nitration in the KATP channel complex. Am J Physiol Gastrointest Liver Physiol. 2015 Mar 15;308(6):G532-9. doi: 10.1152/ajpgi.00281.2014. Epub 2014 Dec 31. PubMed PMID: 25552582; PubMed Central PMCID: PMC4360042.
13: Wöhrle J, Höher M, Nusser T, Hombach V, Kochs M. No effect of highly dosed nitric oxide donor molsidomine on the angiographic restenosis rate after percutaneous coronary angioplasty: a randomized, placebo controlled, double-blind trial. Can J Cardiol. 2003 Apr;19(5):495-500. PubMed PMID: 12717484.
14: Kmieć M, Ochmański W. [Molsidomine: importance in treatment of circulation disorders]. Przegl Lek. 1998;55(10):532-6. Review. Polish. PubMed PMID: 10224868.
15: Uribe P, Boguen R, Treulen F, Sánchez R, Villegas JV. Peroxynitrite-mediated nitrosative stress decreases motility and mitochondrial membrane potential in human spermatozoa. Mol Hum Reprod. 2015 Mar;21(3):237-43. doi: 10.1093/molehr/gau107. Epub 2014 Nov 25. PubMed PMID: 25425609.
16: Darius H, Erbel R, Rupprecht HJ, Pop T, Meyer J. [Acute and chronic effects of molsidomine in therapeutic coronary angioplasty]. Med Klin (Munich). 1990 Feb;85 Suppl 1:23-6. German. PubMed PMID: 2185404.
17: Spreux-Varoquaux O, Doll J, Dutot C, Grandjean N, Cordonnier P, Pays M, Andrieu J, Advenier C. Pharmacokinetics of molsidomine and its active metabolite, linsidomine, in patients with liver cirrhosis. Br J Clin Pharmacol. 1991 Sep;32(3):399-401. PubMed PMID: 1777378; PubMed Central PMCID: PMC1368538.
18: Drummer C, Valta-Seufzer U, Karrenbrock B, Heim JM, Gerzer R. Comparison of anti-platelet properties of molsidomine, isosorbide-5-mononitrate and placebo in healthy volunteers. Eur Heart J. 1991 Apr;12(4):541-9. PubMed PMID: 1648488.
19: Rosenkranz B, Winkelmann BR, Parnham MJ. Clinical pharmacokinetics of molsidomine. Clin Pharmacokinet. 1996 May;30(5):372-84. PubMed PMID: 8743336.
20: Messin R, Bruhwyler J, Dubois C, Famaey JP, Géczy J. Tolerability to 1-year treatment with once-daily molsidomine in patients with stable angina. Adv Ther. 2006 Jul-Aug;23(4):601-14. PubMed PMID: 17050502.
